Ikena Oncology merges with Inmagene; Inmagene shareholders to own 55.6% of combined co.

ImageneBio, Inc.

Pre-PIPE, Inmagene shareholders own ~55.6%, Ikena ~44.4% of combined company.
PIPE financing of $75M from accredited investors, closing simultaneously with merger.
Loan agreement: Ikena to lend Inmagene up to $22.5M (initial $7.5M) secured by IMG-007 asset.
Ikena stockholders to receive CVRs for potential proceeds from pre-merger assets (e.g., IK-595).
Combined company board: 7 members, 3 from Inmagene, 2 from Ikena, 1 mutual, 1 from PIPE lead.

item 1.01 item 3.02 item 5.01 item 5.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.